Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.
2.

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.

Weir MR, Sperling RS, Reicin A, Gertz BJ.

Am Heart J. 2003 Oct;146(4):591-604. Review.

PMID:
14564311
3.

Rofecoxib.

Hillson JL, Furst DE.

Expert Opin Pharmacother. 2000 Jul;1(5):1053-66. Review.

PMID:
11249495
4.

Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.

Hawkey CJ, Jackson L, Harper SE, Simon TJ, Mortensen E, Lines CR.

Aliment Pharmacol Ther. 2001 Jan;15(1):1-9. Review.

5.

Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?

Savage R.

Drugs Aging. 2005;22(3):185-200. Review.

PMID:
15813652
6.

[Is there a future for COX-2 inhibitors?].

Yodfat Y.

Harefuah. 2004 Nov;143(11):820-4, 837. Review. Hebrew.

PMID:
15603272
7.

[Specific inhibitors of cyclooxygenase type 2] ].

Tomasová-Studýnková J.

Vnitr Lek. 2002 May;48(5):403-8. Review. Czech.

PMID:
12061207
8.

Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.

Ahuja N, Singh A, Singh B.

J Pharm Pharmacol. 2003 Jul;55(7):859-94. Review.

PMID:
12906745
9.

Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs.

Phelan KM, Mosholder AD, Lu S.

J Clin Psychiatry. 2003 Nov;64(11):1328-34. Review.

PMID:
14658947
10.

COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.

Ray WA, MacDonald TM, Solomon DH, Graham DJ, Avorn J.

Pharmacoepidemiol Drug Saf. 2003 Jan-Feb;12(1):67-70. Review. No abstract available.

PMID:
12616850
11.

Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?

Hersh EV, Lally ET, Moore PA.

Curr Med Res Opin. 2005 Aug;21(8):1217-26. Review.

PMID:
16083531
12.

[Clinical pharmacology of the selective COX-2 inhibitors].

Burian M, Geisslinger G.

Orthopade. 2003 Dec;32(12):1078-87. Review. German.

PMID:
14655004
13.

Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.

Howard PA, Delafontaine P.

J Am Coll Cardiol. 2004 Feb 18;43(4):519-25. Review.

14.

C-reactive protein and other inflammatory risk markers in acute coronary syndromes.

Blake GJ, Ridker PM.

J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):37S-42S. Review.

PMID:
12644339
15.

Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature.

Morales E, Mucksavage JJ.

Pharmacotherapy. 2002 Oct;22(10):1317-21. Review.

PMID:
12389882
16.

Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity.

West PM, Fernández C.

Ann Pharmacother. 2003 Oct;37(10):1497-501. Review.

PMID:
14519044
17.

Aspirin and NSAID sensitivity.

Stevenson DD.

Immunol Allergy Clin North Am. 2004 Aug;24(3):491-505, vii. Review.

PMID:
15242723
18.
19.

COX-2 inhibitors: a review.

Houston AM, Teach SJ.

Pediatr Emerg Care. 2004 Jun;20(6):396-9; quiz 400-2. Review. No abstract available.

PMID:
15179150
20.

Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea.

Harel Z.

J Pediatr Adolesc Gynecol. 2004 Apr;17(2):75-9. Review.

PMID:
15050982

Supplemental Content

Support Center